AstraZeneca plc (AZN)
| Market Cap | n/a |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | n/a |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,735,897 |
| Open | 76.26 |
| Previous Close | 76.21 |
| Day's Range | 75.84 - 76.74 |
| 52-Week Range | 62.75 - 87.68 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About AZN
There is no company description available. [Read more]
Financial Performance
In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.
Financial StatementsNews
Neurofibromatoses Therapeutics Competitive Landscape Report 2024: Pipeline Holds 35 Molecules - Currently Only 1 Approved Innovator Drug, AstraZeneca's (Koselugo/Coselugo) Selumetinib Sulfate
Dublin, Feb. 28, 2025 (GLOBE NEWSWIRE) -- The "Neurofibromatoses: Competitive Landscape" report has been added to ResearchAndMarkets.com's offering. This reports provides a data-driven overview of the...
BioInvent International AB: Year-End Report January 1 - December 31, 2024
LUND, SWEDEN / ACCESS Newswire / February 27, 2025 / BioInvent International (STO:BINV) "2024 was a year with several exciting developments reported from across our broad portfolio of clinical program...
Camizestrant demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival in 1st-line advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from a planned interim analysis of the SERENA-6 Phase III trial showed that AstraZeneca's camizestrant in combination with a cyclin-depen...
AstraZeneca therapy improves survival in late-stage breast cancer trial
Pharmaceuticals major AstraZeneca said on Wednesday that its experimental treatment, camizestrant, improved survival in patients with an advanced form of breast cancer without the disease getting wors...
Final Trades: Starbucks, Astrazeneca, Western Union and the IYR
The Investment Committee give you their top stocks to watch for the second half.
Leading Healthcare Institutions Adopt MSK-ACCESS® for Liquid Biopsy Testing
SOPHiA GENETICS enables institutions across the globe to launch world-class oncology testing BOSTON, MA and ROLLE, Switzerland, Feb. 24, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a pioneer ...
Final Deadline for the AstraZeneca PLC Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - AZN
LOS ANGELES , Feb. 20, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ: AZN) for violations of the f...
AstraZeneca to Buy Fusion Pharmaceuticals for Up to $2.4B as Firm Expands Cancer Pipeline
AstraZeneca Plc (AZN) on Tuesday said it will acquire biotech company Fusion Pharmaceuticals Inc. (FUSN) for up to $2.4 billion, expanding its pipeline of treatment for advanced prostate cancer.
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of February 21, 2025 in AstraZeneca PLC Lawsuit – AZN
NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of AstraZeneca PLC (NASDAQ: AZN).
Amid Mounting Pressure In China, AstraZeneca Buys FibroGen's Chinese Unit For $160 Million
FibroGen Inc. FGEN stock is trading higher on Thursday. The company announced the sale of its China subsidiary to AstraZeneca Plc AZN for approximately $160 million.
FibroGen sells China unit to AstraZeneca in deal worth $160 million
FibroGen said on Thursday that it has sold its China unit to AstraZeneca for about $160 million.
AstraZeneca Post 2024 Earnings: Unwanted Headwinds Warrant Downgrade To Hold
AstraZeneca PLC beat Q4 and full-year 2024 earnings estimates, with significant revenue and EPS growth, and forecasts further growth in 2025 despite China-related setbacks. The company faces challenge...
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AstraZeneca
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In AstraZenecaTo Contact Him Directly To Discuss Their Options
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AstraZeneca
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In AstraZenecaTo Contact Him Directly To Discuss Their Options NEW YORK, NY / ACCESS Ne...
AstraZeneca (AZN) Reels from China Investigation and Investor Suit – Hagens Berman
AZN Investors with Losses Encouraged to Contact the Firm Before Feb. 21, 2025 Deadline AZN Investors with Losses Encouraged to Contact the Firm Before Feb. 21, 2025 Deadline
New Interactive Storybook Aims to Educate Children with Rare Kidney Disease into a World of Adventure and Understanding
LONDON--(BUSINESS WIRE)--New Interactive Storybook Aims to Educate Children with Rare Kidney Disease into a World of Adventure and Understanding.
AstraZeneca (AZN) Reels from China Investigation and Investor Suit - Hagens Berman
AZN Investors with Losses Encouraged to Contact the Firm Before Feb. 21, 2025 Deadline SAN FRANCISCO, CA / ACCESS Newswire / February 11, 2025 / AstraZeneca (NASDAQ:AZN), the Anglo-Swedish pharmaceuti...
Final Trades: Trade Desk, Leidos Holdings, Astrazeneca and Devon Energy
The Investment Committee give you their top stocks to watch for the second half.
AstraZeneca PLC (AZN) Q4 2024 Earnings Call Transcript
AstraZeneca PLC (NASDAQ:AZN) Q4 2024 Earnings Conference Call February 6, 2025 6:00 AM ET Company Participants Pascal Soriot – Executive Director and Chief Executive Officer Iskra Reic – Executive Vi...
AstraZeneca Q4 Earnings: Revenue And EPS Beat On Higher Cancer And Respiratory Drug Sales, Faces $4.5 Million Potential Fine In China
On Thursday, AstraZeneca Plc AZN reported fourth-quarter sales of $14.89 billion, up 18% year over year (+19% at constant currency), beating the consensus of $14.29 billion.
AstraZeneca's Full Year and Q4 2024 results
CAMBRIDGE, England--(BUSINESS WIRE)--AstraZeneca: Revenue and EPS summary FY 2024 % Change Q4 2024 % Change $m Actual CERi $m Actual CER - Product Sales 50,938 16 19 13,362 18 19 - Alliance Revenu...
AstraZeneca 2025 sales outlook tops expectations
AstraZeneca forecast its 2025 sales above analysts' expectations on Thursday, after the drugmaker's fourth-quarter revenue beat estimates, driven by robust demand, especially for its medicines for can...
AstraZeneca shareholders say they need clarity on China investigations
AstraZeneca investors will look past another strong set of quarterly results on Thursday to focus on the main issue overhanging shares: an investigation of a top executive by authorities in China, one...
UK hits back at AstraZeneca over collapse of investment deal
Britain on Monday hit back at AstraZeneca over the collapse of a 450 million pound ($558.5 million) investment, saying the drugmaker had scaled back the research and development portion of its plans, ...
AstraZeneca ditches plan to build $558 mln UK vaccine plant
AstraZeneca is no longer pursuing plans for a 450 million pound ($558.32 million) vaccine manufacturing plant in Speke, Liverpool, a company spokesperson said on Friday.